Korean J Infect Dis.
2000 Aug;32(4):274-279.
In Vitro Activities of LY303366 against Clinical Isolates of Candida spp., Cryptococcus neoformans and Aspergillus spp.
- Affiliations
-
- 1Department of Clinical Pathology, Yonsei University College of Medicine, Seoul, Korea.
- 2Research Institute of Bacterial Resistance, Yonsei University College of Medicine, Seoul, Korea.
Abstract
- BACKGROUND
Fungal infection became more prevalent with the increase of compromised patients, requiring less toxic potent antifungal agents. LY303366, a new semisynthetic antifungal agent of echinocandin class, was reported to be active against Candida spp. and filamentous fungi.
METHODS
In vitro activities of LY303366 were determined against clinical isolates of fungi by NCCLS broth microdilution test using RPMI 1640 medium.
RESULTS
MIC90s of LY303366 were 0.03 microgram/mL for C. albicans, 2 microgram/mL for C. parapsilosis, 0.12 microgram/mL for C. tropicalis. LY303366 was more active against C. albicans and C. tropicalis than amphotericin B, 5-fluorocytosine, or fluconazole. It was less active than other agents against C. neoformans. MIC range of LY303366 against Aspergillus spp. was 8->16 microgram/mL.
CONCLUSION
Very high in vitro activity of LY303366 against recent clinical isolates of Candida spp. including fluconazole resistant ones, suggests its usefulness for the treatment of candidal infections.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- In vitro Evaluation of the Antifungal Activity of Propolis Extract on Cryptococcus neoformans and Candida albicans
- Genotypes of Clinical and Environmental Isolates of Cryptococcus neoformans and Cryptococcus gattii in Korea
- Isolation of Cryptococcus neoformans var. grubii (serotype A) from Pigeon Droppings in Korea
- Lipolytic Enzymes Involved in the Virulence of Human Pathogenic Fungi
- Differentiation of Varieties and Susceptibility Testing for Two Strains of Cryptococcus neoformans
